These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11558706)

  • 1. The link between gross profitability and pharmaceutical R&D spending.
    Scherer FM
    Health Aff (Millwood); 2001; 20(5):216-20. PubMed ID: 11558706
    [No Abstract]   [Full Text] [Related]  

  • 2. Probing the link between gross profitability and R&D spending.
    Lichtenberg FR
    Health Aff (Millwood); 2001; 20(5):221-2. PubMed ID: 11558707
    [No Abstract]   [Full Text] [Related]  

  • 3. A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness.
    Refoios Camejo R; McGrath C; Herings R
    Health Policy; 2011 Apr; 100(1):18-24. PubMed ID: 20864202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examining the link between price regulation and pharmaceutical R&D investment.
    Vernon JA
    Health Econ; 2005 Jan; 14(1):1-16. PubMed ID: 15386673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection of licensing candidates in the pharmaceutical industry: an application of the analytic hierarchy process.
    Ross ME; Nydick RL
    J Health Care Mark; 1992 Jun; 12(2):60-5. PubMed ID: 10119215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of health care reform on research innovativeness.
    Pickett C
    Ann N Y Acad Sci; 1994 Nov; 729():106-10; discussion 139-42. PubMed ID: 7998721
    [No Abstract]   [Full Text] [Related]  

  • 7. Why is the pharmaceutical industry investing increasing amounts in health economic evaluations?
    Andersson F
    Int J Technol Assess Health Care; 1995; 11(4):750-61. PubMed ID: 8567207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. America's pharmaceutical research companies: keeping the cost of health care down. Pharmaceutical Manufacturers Association.
    Hawaii Med J; 1992 Jan; 51(1):15-16, 19. PubMed ID: 1740387
    [No Abstract]   [Full Text] [Related]  

  • 9. Merck's recall of rofecoxib--a strategic perspective.
    Oberholzer-Gee F; Inamdar SN
    N Engl J Med; 2004 Nov; 351(21):2147-9. PubMed ID: 15548771
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmaceutical downsizing and oncology drug development.
    Senior K
    Lancet Oncol; 2008 Jan; 9(1):11. PubMed ID: 18183658
    [No Abstract]   [Full Text] [Related]  

  • 11. Will R&D make Merck hot again?
    Simons J
    Fortune; 2002 Jul; 146(1):89-90, 92, 94. PubMed ID: 12119729
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmaceuticals. Record spending on R&D.
    Hosp Health Netw; 1996 Mar; 70(6):12. PubMed ID: 8593496
    [No Abstract]   [Full Text] [Related]  

  • 13. Costing drug development.
    Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358
    [No Abstract]   [Full Text] [Related]  

  • 14. The opportunity cost of capital: development of new pharmaceuticals.
    Chit A; Chit A; Papadimitropoulos M; Krahn M; Parker J; Grootendorst P
    Inquiry; 2015; 52():. PubMed ID: 25933615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taking clinical trials to task.
    Drummond M
    Value Health; 2005; 8(5):517-8. PubMed ID: 16176489
    [No Abstract]   [Full Text] [Related]  

  • 16. Raising the standards of trial-based economic evaluation: the devil is in the detail.
    Backhouse ME
    Value Health; 2005; 8(5):519-20. PubMed ID: 16176490
    [No Abstract]   [Full Text] [Related]  

  • 17. Potential stifling effects of pharmaco-economics and regulatory policies.
    Data JL
    Am J Cardiol; 1998 Apr; 81(8A):34F-35F. PubMed ID: 9604904
    [No Abstract]   [Full Text] [Related]  

  • 18. Risks and benefits of importing prescription medications from lower-income countries.
    Dhalla IA; Detsky AS
    JAMA; 2008 Sep; 300(12):1453-5. PubMed ID: 18812537
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost of innovation in the pharmaceutical industry.
    DiMasi JA; Hansen RW; Grabowski HG; Lasagna L
    J Health Econ; 1991 Jul; 10(2):107-42. PubMed ID: 10113009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opinion: development of new drugs is still a risky business.
    Franks B
    N J Med; 2002; 99(1-2):60, 59. PubMed ID: 15326736
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.